Benjamin DAMIEN | CEO
Sagitta Biotech

Benjamin Damien is an innovative player and seasoned professional in the biotech industry, currently serving as the CEO of Sagitta Biotech.
With over 22 years of experience in research, development, and strategic partnering within the global vaccine industry, Benjamin has a proven track record of driving innovation and delivering impactful solutions.

Throughout his career, Benjamin has been at the forefront of cutting-edge research and development initiatives, participating to the creation and/or managing over 15 innovative biotechs, in Belgium, France and the Netherlands.

Benjamin is known for his passion for improving global health outcomes through the development of safe and effective vaccines. His commitment to excellence, combined with his ability to navigate complex regulatory environments, has positioned Sagitta Biotech as a key player in the fight against infectious diseases.

As a speaker at the World Vaccine Congress Europe 2025, Benjamin brings valuable insights and expertise to the discussion on research, development, and strategic partnering in the vaccine industry. His thought leadership and innovative approach make him a sought-after expert in the field, driving meaningful conversations and shaping the future of vaccine development.

With a strong focus on collaboration, innovation, and impact, Benjamin continues to lead Sagitta Biotech towards new frontiers in vaccine research and development, making a lasting contribution to global public health.